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Abstract
Hemorrhagic meningitis is a fatal complication of anthrax, but its pathogenesis remains poorly understood. The present
study examined the role of B. anthracis-secreted metalloprotease InhA on monolayer integrity and permeability of human
brain microvasculature endothelial cells (HBMECs) which constitute the blood-brain barrier (BBB). Treatment of HBMECs
with purified InhA resulted in a time-dependent decrease in trans-endothelial electrical resistance (TEER) accompanied by
zonula occluden-1 (ZO-1) degradation. An InhA-expressing B. subtilis exhibited increased permeability of HBMECs, which did
not occur with the isogenic inhA deletion mutant (DinhA)o fB. anthracis, compared with the corresponding wild-type strain.
Mice intravenously administered with purified InhA or nanoparticles-conjugated to InhA demonstrated a time-dependent
Evans Blue dye extravasation, leptomeningeal thickening, leukocyte infiltration, and brain parenchymal distribution of InhA
indicating BBB leakage and cerebral hemorrhage. Mice challenged with vegetative bacteria of the DinhA strain of B.
anthracis exhibited a significant decrease in leptomeningeal thickening compared to the wildtype strain. Cumulatively,
these findings indicate that InhA contributes to BBB disruption associated with anthrax meningitis through proteolytic
attack on the endothelial tight junctional protein zonula occluden (ZO)-1.
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Introduction
Bacillus anthracis is a gram-positive, spore-forming, rod-shaped
bacterium that causes three distinct clinical forms of anthrax
depending on the major routes of infection: inhalational,
cutaneous, and gastrointestinal [1]. All forms of anthrax can be
highly lethal if left untreated, due to systemic spread of bacteria
through hematogenous and lymphatic routes. At the systemic
stage, anthrax is accompanied by damage to many organs and
tissues. Clinical case reports indicate that bacteria disseminated to
the brain can cause hemorrhagic meningitis, a life-threatening
pathology manifested as a ‘‘cardinal’s cap’’, due to the character-
istic appearance of meninges upon autopsy [1–4]. During the
epidemic of inhalation anthrax in Sverdlovsk, Russia, fatal
hemorrhagic meningitis was reported in 50% of the individuals
infected with aerosolized B. anthracis spores [3,4]. Further studies
revealed that 79% of all cases contained bacilli in meninges, and
low-pressure meningeal hemorrhages were found in 90% of all
autopsies [4]. Under physiological conditions, access of pathogens
or macromolecules to the central nervous system (CNS) is
restricted by the anatomic and functional unit called the blood-
brain barrier (BBB) which is selectively permeable to some
hormones and nutrients. Histopathological analysis indicates that
during anthrax the secreted pathogenic factors of B. anthracis exert
devastating effects on the BBB, rendering it leaky and permeable
[2–4].
The major virulence determinants of B. anthracis are encoded by
two large plasmids, pXO1 and pXO2. The genes for the Lethal
Toxin (LT) and Edema Toxin (ET) are located on pXO1, and
genes for the anti-phagocytic poly-c-D-glutamic acid capsule are
located on pXO2. LT is a specific protease inactivating mitogen-
activated protein kinases in the host cells, while ET is an adenylate
cyclase. Both toxins influence a broad spectrum of cellular
functions, including changes in vascular permeability leading to
barrier dysfunction manifested as tissue edema and pleural
effusions [5]. However, the activity of LT and ET cannot fully
account for several pathological findings of anthrax, such as
massive hemorrhages, intensive organ and tissue damage, and
other immune consequences including degradation of cytokines
and immunoglobulins, as observed in mice treated with culture
filtrates of B. anthracis [6]. The disseminated tissue damage suggests
that some secreted B. anthracis protease(s) distinct from LT may
also serve a pathogenic role. Moreover, several bacterial proteases
from species other than B. anthracis have been known to cause
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10]. We recently purified from culture supernatant of B. anthracis
two zinc metalloproteases: Neutral Protease 599 (Npr599 or
NprB), a thermolysin-like protease, and Immune Inhibitor A
(InhA), a homolog of B. thuringiensis protease [11]. The ability of
these proteases to degrade plasma and matrix proteins in vitro
suggests their role in endothelial barrier permeability and blood
homeostatic imbalance during the infectious process [11–13].
The structural and functional integrity of the BBB primarily
depends on the state of brain capillaries and its polarized
microvascular endothelial cells which possess tight junction (TJ)
[14]. Intercellular TJ proteins include occludin, claudin, junctional
adhesion molecules (JAMs), and membrane-associated guanylate
kinase-like proteins (MAGUK) or zonula occludens (ZO)-1 [15].
Their function is to regulate paracellular passage of substrates
across the BBB. ZO-1 is associated with TJ proteins and the actin
cytoskeleton, and is essential for the stability, organization and
signaling of TJ proteins; loss or dissociation of the protein from its
counterparts has been implicated in increasing barrier permeabil-
ity [16–19]. It has been recently shown that proteolytic breakdown
of the microvascular endothelial cell monolayers by B. anthracis is
associated with degradation of ZO-1, a process which requires
adhesion of bacteria to endothelium through the S-layer adhesin
BslA [20]. Some bacterial proteases can unravel junctional
complexes in endothelial and epithelial cells, thereby inducing
barrier permeability in non-CNS tissues [21].
In the present study, we tested whether InhA plays a role in
BBB permeability associated with anthrax meningitis. Using
HBMECs as an in vitro model of BBB we demonstrate that
increased permeability takes place upon internalization of InhA
into HBMECs followed by degradation of ZO-1. Experiments
with mice challenged with purified InhA or vegetative bacteria of
the DinhA strain of B. anthracis indicate that expression of InhA
contributes to hemorrhagic brain damage associated with fatal
meningitis.
Materials and Methods
Protease isolation and purification
Npr599 and InhA were isolated from culture supernatant of B.
anthracis Sterne 34F2 (devoid of both pXO1 and pXO2) and
purified as described previously [11]. Protease gelatin hydrolytic
activity was determined using the EnzChek gelatinase/collagenase
kit (Molecular Probes) according to manufacturer’s protocol.
Real-time TEER measurements
Frozen stocks of HBMECs between passages 8 and 24 were
thawed and then maintained as previously described [22] in RPMI
1640-based medium with growth factors, 10% fetal bovine serum
(FBS), of endothelial cell growth supplement (30 mg/ml), heparin
(5 U/ml), L-glutamine (2 mM), sodium pyruvate (1 mM), non-
essential amino acids, vitamins, penicillin and streptomycin
(100 U/ml). Cultures were incubated at 37uC in a humid
atmosphere of 5% CO2 and split in a ratio of 1:3 twice a week.
During experiments, the original RPMI1640-based culture
medium was replaced with the medium (XM) containing 1:1
ratio of Medium 199 and Ham’s F-12 medium, 5% heat-
inactivated FBS, and 1 mM glutamine [22]. To estimate the
integrity of the HBMECs monolayers the electric cell–substrate
impedance sensing (ECIS) system was used to measure and
monitor TEER in HBMECs as described in [23]. Cells were
grown on gold-coated electrodes (0.8 cm
2 per well) in microelec-
trode 8W10E
+ ECIS arrays (Applied BioPhysics, NY). The voltage
between the small electrode and the large counter electrode was
monitored by a lock-in amplifier, stored, and processed by
computer-controlled instrumentation (Applied Biophysics, NY).
The electrodes/wells were coated with 50 mg/ml of rat tail
collagen (BD Bioscience) prior to being washed by culture
medium. HBMECs were seeded at 2610
4 cells/well and allowed
to grow to confluence. At cell confluence, the culture medium was
replaced with XM and allowed to equilibrate for 2 h within the
ECIS setup prior to adding InhA and Npr599. InhA (1 mg/ml) or
Npr599 (1 mg/ml) were added to the apical aspect of cells in the 8-
well cell culture arrays. For bacterial infection, the recombinant B.
subtilis 168 transformed with the InhA-expressing plasmid [24] was
used as a gain-of function strain. The DinhA of B. anthracis Ames 35
(attenuated Ames strain lacking pXO2) generously provided by
Dr. S. Leppla (National Institutes of Health) was used as a loss-of-
function strain [13]. Bacteria of the mutant and corresponding
isogenic parental strains were cultured overnight in LB media and
then added to the HBMEC monolayers (about 6610
4 cells/well)
at different multiplicities of infection (MOI). TEER in each well
was measured at 2-min intervals for 24 h and was recorded as an
average of signals from duplicate wells. Differential interference
contrast microscopy was used to observed morphological changes
of the exposed HBMECs cell monolayers after 24 h.
Dextran permeability assay
Cells were seeded on collagenized transwell inserts (6.5 mm
diameter, 0.4 mm pore size, Corning-Costar), grown for 7 days at
37uC in the atmosphere of 5% CO2, and then treated with the
indicated amount of proteases or culture supernatants for 24 h.
After incubation, culture medium in the upper chamber was
replaced with Hanks Balanced Salt Solution (HBSS) containing
0.5 mg/ml of FITC-dextran (MW 40 kDa) for 2 h. Leakage of
FITC-dextran to the bottom chamber was measured with a
fluorescence microplate reader at 538 nm after excitation at
485 nm. Positive control included incubation with the supernatant
of B. anthracis deltaSterne (pXO1
2, pXO2
2) culture grown
overnight in a shaking incubator at 300 rpm in LB medium at
37uC and then diluted ten-fold with cell culture medium.
Preparation of recombinant ZO-1 (rZO-1) protein
fragment
PCR amplification of ZO-1 cDNA obtained from ATCC (Gene
Bank Number: BC111712) was done using specific primers
(forward 59-TCA GAT GTA GGA GAT TCT TTC-39 and
reverse 59-ATG CTG AGA TGA AGG TAT CAG-39), the
product was inserted into pTRcHis II TOPO (TOPO TA cloning
kit, Invitrogen) and transformed into E. coli DH5-a cells.
Positive transformants were selected and verified by restriction
mapping and sequencing. Expression of ZO-1 protein fragments
in DH5-a cell cultures was induced by IPTG and the His6-tagged
products were purified by Ni
2+-NTA resin (Invitrogen). Purified
recombinant proteins were incubated with InhA at molar ratio of
10:1 in 50 mM Tris-HCl, pH 7.5, 2 mM CaCl2 at 37uC, and the
resulting products were analyzed by Western blotting using the
anti-His6 antibody (Invitrogen) to determine their molecular
masses and the positions of InhA cleavage sites.
ZO-1 degradation, SDS-PAGE and Western blot analysis
HBMECs (2610
6 cells) were treated with Npr599 (1 mg/ml) or
InhA (1 mg/ml) at 37uC for different times, washed twice with
HBSS, and lysed with RIPA buffer (Pierce) containing 1% Triton
X-100 (Sigma) and 1x protease inhibitor cocktail (Pierce). Lysates
were centrifuged at 14,000 g for 10 min and supernatants
collected. InhA (1, 0.1, and 0.01 mg/ml) was also used to treat
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protein at 37uC for 4 h. For Western blot analysis, samples were
boiled in SDS sample buffer containing 30 mM dithiothreitol.
Proteins were separated on a 4–12% Bis-Tris or 6% Tris-Glycine
gels (Invitrogen) and transferred onto nitrocellulose membranes
using the iBlot Gel Transfer System (Invitrogen). The membranes
were blocked with 5% milk powder in PBS and probed with
antibodies against ZO-1 (Invitrogen), occludin (Invitrogen),
claudin-1 (Invitrogen) and JAM-1 (Chemicon). After washes,
membranes were incubated with appropriate peroxidase-coupled
secondary antibodies (Amersham Biosciences) and developed with
Super Signal West-Femto chemiluminescent substrate (Pierce).
Visualization of the blots was done with ChemiDoc XRS imager
(BioRad).
Immunostaining and fluorescence microscopy
Confluent HBMEC monolayers treated with purified InhA
were washed three times with PBS, fixed with 2% paraformalde-
hyde in PBS for 15 min, and permeabilized with 0.5% Triton X-
100 in PBS for 20 min. The cells were further incubated with the
mouse anti-human ZO-1 (Zymed) or the rabbit anti-InhA
antibody (custom made as described below) in PBS containing
5% fetal calf serum for 1 h, washed three times with PBS, and
then incubated with the FITC-conjugated goat anti-mouse or the
mouse anti-rabbit antibodies in PBS containing 5% fetal calf
serum. After incubation, cells were washed with PBS, stained with
DAPI ProLong Gold antifade reagent (Invitrogen), and visualized
with a Nikon confocal 90i microscope.
Tissue section slides were deparaffinized, re-hydrated, fixed with
4% paraformaldehyde for 10 min, rinsed three times with PBS,
and blocked with 1.5% goat serum PBS solution for 30 min at
4uC. Slides were washed again and incubated with the primary
anti-InhA antibody at 4uC overnight, followed by the correspond-
ing FITC-labeled secondary antibody as described above. The
anti-InhA antibody used in these experiments was raised in rabbits
against the N-terminal fragment CPAKQKAYNGDVRKD of the
active form of InhA and purified from the immune serum by
peptide affinity chromatography (Invitrogen).
In vivo BBB permeability assays
Female, 9-week-old DBA/2 mice (Jackson Laboratory) were
maintained at Biocon, Inc. (Rockville, MD). Institutional Animal
Care and Use Committees at George Mason University and
Biocon, Inc. approved all protocols. Mice were anesthetized by
injection of 90 mg/kg of ketamine and 10 mg/kg of xylazine and
then one unit of purified InhA in phosphate-buffered saline per
mouse was injected via a retro-orbital route. One unit is defined as
the amount of enzyme in 1 ml required to liberate 1 mmol of L-
leucine from collagen (100 mg/ml) in 5 h at 37uC, pH 7.5.
Approximately 1 h before each time point, animals were injected
with a 100 ml of Evans Blue (EB) dye (1% w/v solution) through
the tail vein and then perfused with 10 ml of PBS 1 h later
through the apex of the heart [25]. The brains were then removed,
weighed and homogenized in 1.5 ml of PBS. To extract the EB
dye from the tissue homogenate, 1.5 ml of trichloroacetic acid
(60% w/v) were added to each sample. The homogenate solution
was vortexed for 2 min and then centrifuged for 30 min at 4uCa t
1000 g. The EB supernatant was collected and absorbance
measured on plate reader at 620 nm, and the background
absorbance subtracted. Extravasation of dye was expressed as mg
of EB dye per g of brain.
Similar to experiments with purified InhA, animals were
injected with 100 ml of Quantum Dot nanoparticles (Invitrogen)
conjugated with one unit of active or heat-inactivated protease.
Nanoparticles-conjugated to InhA was prepared using QdotH
ITK
TM carboxyl Quantum Dots according to manufacturer’s
recommendation (Invitrogen). Control mice were injected with
equal volume of nanoparticles alone. After approximately 24 h,
the animals were euthanized, the brains were removed and
immersed in 10% buffered formalin for fixation. The 5-mm
sections of fixed brains were stained with hematoxylin and eosin
(H&E) for further histological analysis by AML Laboratories
(Rosedale, MD). Immunofluorescent detection of nanoparticles
containing a red fluorophore (emission at 585 nm) was performed
using fluorescence microscopy. InhA was immunostained using
rabbit a-InhA primary antibody and a FITC-conjugated mouse
anti-rabbit antibody.
Mouse infection studies
For a meningitis model, the DinhA of Ames 35 strain (DinhA) and
the wildtype Ames 35 strain were grown overnight in luria broth.
Pelleted bacteria were washed in PBS and 5610
4 or 5610
5 CFU
in 0.1 ml of PBS were injected intravenously into 9-week-old
female DBA/2 mice (n=5 per each group). To determine a mean
time-to-death, mice were monitored daily for 7 days. For
histological analyses, mice (n=8 per each group) were injected
with 5610
5 CFU of vegetative bacteria and euthanized when they
become moribund. Blood and brain were collected and bacterial
loads were determined by CFU, serial dilutions plated on agar.
Statistical analysis
P-values were calculated by one-way ANOVA. Statistical
significance was set at p,0.05. Data are presented as arithmetic
mean 6 SD.
Results
Secreted B. anthracis metalloprotease InhA increases
permeability of HBMEC monolayers
The effect of InhA on the integrity of human BBB was
examined in vitro using HBMEC monolayers. A real-time TEER
was used to measure barrier integrity and changes in confluent
monolayer permeability. As shown in Figure 1A, InhA-treated
HBMECs exhibited a progressive drop in TEER over time, while
the mock-treated control and neutral protease (Npr599)-treated
HBMECs did not exhibit a decrease in TEER. At 24 h post-
exposure, TEER of the InhA-treated monolayers dropped to
approximately 60% compared to the value observed in the mock-
treated control. At the 24 h time point, the differential interference
contrast microscopy revealed gaps in the InhA-treated HBMECs
as well as the detachment of the cells from the slide surface
(Figure 1B). In the case of mock- and Npr599-treated cells, the
monolayers remained intact and displayed no change in
morphology. HBMEC monolayers were also assayed by the
transmigration of FITC-dextran (Figure 1C). Incubation of the
cells with InhA and B. anthracis deltaSterne culture supernatant
significantly increased monolayer permeability, whereas o-phe-
nanthroline (100 mM) an inhibitor of metalloproteases abrogated
the permeabilizing activity of InhA and the bacterial culture
supernatant. There were no significant changes in viability of
HBMECs during treatments with the proteases and culture
supernatant (not shown). These data demonstrate the ability of
the InhA to increase permeability of HBMEC monolayers in vitro.
Cytoplasmic protein ZO-1 is a target for InhA
BBB function is defined by the state of its TJ proteins and the
proteins associated with them in the cell. A decrease in barrier
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[15]. We therefore examined whether InhA caused degradation of
TJ proteins in HBMECs. Western blot analysis of HBMEC cell
lysates after 24 h incubation with purified InhA showed
degradation of ZO-1 but not claudin-1, occludin, or JAM-1 in a
concentration-dependent manner (Figure 2A, B). As a control,
heat-inactivated InhA did not degrade any of the above-
mentioned TJ proteins (not shown). Initial signs of ZO-1
degradation by InhA were observed as early as 20 min after
treatment, while a complete loss of ZO-1 was observed after 24 h
(Figure 2C). Notably, Npr599 was unable to cleave ZO-1 in
HBMECs; instead, it increased ZO-1 levels. Immunofluorescence
microscopy confirmed the loss of ZO-1 upon treatment with InhA
(Figure 2D, panel b). These results suggest that ZO-1 is a
biologically relevant target of InhA in HBMECs. However, in
order to access the cytoplasmic ZO-1 InhA has to be transported
into the cell.
As ZO-1 is a cytoplasmic protein, we tested whether InhA could
access this protein through an endocytic process. HBMECs were
pre-treated with cytochalasin D, a known potent inhibitor of
endocytosis. The pre-treated cells did not show any degradation or
punctuation of ZO-1 upon further treatment with InhA
(Figure 2D-d), indicating that degradation of ZO-1 took place
after InhA entered the cell through endocytotic trafficking, a
process requiring actin polymerization.
To examine whether the observed proteolytic action on ZO-1 in
HBMECs can be attributed to InhA alone, or to any other
intrinsic cellular proteases that might be activated in response to
InhA, we generated rZO-1 protein using recombinant E. coli
expression system. Because of difficulty in expressing a large ZO-1
molecule in E. coli, we chose a middle segment of ZO-1 based on
our assessment of its proteolytic susceptibility to InhA (not shown).
Purified rZO-1was incubated with InhA over different time
periods. Western blot showed that InhA induces a time-dependent
degradation of rZO-1 yielding several fragments (Figure 2E). This
result demonstrates that ZO-1 is susceptible to cleavage by InhA
and thus supports a possibility of direct interaction between these
proteins in the cell. We were able to assign putative cleavage
Figure 1. Real-time TEER of HBMEC monolayers and phase contrast microscopy. (A) Confluent HBMEC monolayers were treated at 37uC for
24 h in the atmosphere of 5% CO2 with 1 mg/ml of either InhA (red) or Npr599 (blue). Average traces of two wells were recorded in two-minute
intervals for a 24-h period. The bars show the extent of variability between independent wells. The arrow marks the addition of protease. (B) Phase
contrast microscopy of HBMEC monolayers at 24 h post treatment. The arrows point to gaps formed in the monolayers of HBMECs after treatment
described in (A). InhA, center panel; Npr599, right panel; mock-treated control, left panel; 100x magnification. (C) Transwell permeability assay of
HBMECs treated as in (A). Positive control included treatment with B. anthracis culture supernatants (Sups) diluted 10-fold with cell culture medium in
the absence (white bar) or presence (red bar) of o-phenanthroline (100 mM). Leakage of FITC-dextran across monolayers was determined as described
in Materials and Methods. All measurements were made in triplicates, and the experiment was repeated twice. NT, control untreated cells.
doi:10.1371/journal.pone.0017921.g001
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InhA (0.1, 0.3, 1, 3 mg/ml from left to right) for 24 h at 37uC. Western blots were probed with antibodies to ZO-1 (225 kDa), occludin (56 kDa), claudin-
1 (22 KDa), and JAM-1 (39 kDa). (B) Densitometry of ZO-1 protein bands from (A). All samples analyzed (n=4) were normalized to the intensity of
corresponding b-actin bands. (C) Western blot analysis of time-dependent degradation of ZO-1 in HBMECs. Black arrows indicate two isoforms for ZO-
1. C, control; N, Npr599; and I, InhA; a+ and a-, two splice variants of a domain. (D) Immunofluorescence of ZO-1 in HBMECs treated with or without
0.25 mg/ml of cytochalasin D for 1 h prior to incubation with varying concentrations of InhA at 37uC for 12 h. Panels show HBMECs treated as follows:
untreated (a); InhA-treated (b); cytochalasin D-treated (c); InhA-treated after cytochalasin D treatment (d). Scale bar: 20 mm. (E) Western blot of His6-
tagged rZO-1. Degradation of purified rZO-1 after treatment with 0.1 mg/ml of InhA for indicated time at 37uC. Putative cleavage sites within the rZO-
1fragment after treatment with InhA were deduced from immunoblot using the molecular masses of the cleavage products. SH3, Src homology 3;
GK, guanylate kinase homolog; a, 80-amino-acid splice variant; -, acidic domain; PRK, proline-rich domain. b-Actin band intensity was used as a
loading control for all Western blots. The results shown in (A)-(D) are representative of 4 independent experiments.
doi:10.1371/journal.pone.0017921.g002
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domain, based on the molecular weight of the fragments seen in
the Western blot probed with a-His6-tag antibody (Figure 2E).
Three of the cleavage sites are located within the occludin binding
domain, suggesting that InhA might be able to disrupt ZO-1’s
interaction with occludin.
InhA disrupts the HBMEC monolayers in vitro and the
BBB in vivo
The results presented above strongly suggest that InhA is a
potent enzyme capable of increasing barrier permeability of
HBMEC monolayers in vitro. To explore whether InhA can disrupt
the integrity of HBMEC monolayers during the infectious process,
we first conducted real-time TEER assays using HBMECs
exposed to growing bacteria. Initial experiments with the DinhA
of B. anthracis Ames 35 in comparison with the wildtype detected a
reduced capacity of DinhA to disrupt the HBMEC barrier
(Figure 3A). However, the inhA deletion had a relatively small
effect on the dynamics of TEER drop, indicating that pathogenic
factors other than InhA (e.g. toxins) also may contribute to the
TEER changes. To study the effect of InhA in the absence of toxin
expression, we generated InhA-expressing non-pathogenic B.
subtilis [24]. B. subtilis inhA transformant induced approximately a
2 h earlier TEER drop than the wildtype B. subtilis 168 (Figure 3B).
The results of TEER measurements are supported by the
transmigration assay of infected monolayers using FITC-conju-
gated dextran (Figure 3C). Western blot analysis of bacterial cells
and culture supernatants confirmed that B. subtilis inhA-transfor-
mant expressed InhA at the level comparable with B. anthracis
Ames 35 (not shown). These data demonstrate that InhA produced
by growing bacteria contributes to a combined permeabilizing
effect of B. anthracis pathogenic factors on HBMECs monolayers.
To extend this observation to in vivo BBB permeability, Evans
Blue (EB) dye extravasation assay in the mouse brain was
Figure 3. InhA contributes to increased permeability of infected HBMEC monolayers. (A, B) Real-time TEER of HBMECs (about 6610
4 cells/
well) treated with DinhA of B. anthracis Ames 35 (DinhA, red line in panel A) and InhA-expressing B. subtilis (inhA+, red line in panel B) at MOI of 10.
Signals corresponding to parental strains (WT) and culture medium without bacteria are shown as blue and black lines, respectively. Arrows indicate
time points when bacteria were added to the cells. (C) Transwell permeability assays of HBMECs infected with B. anthracis (Ba) and B. subtilis (Bs)
strains as indicated above for 4 h. Leakage of FITC-dextran added to the monolayers for 2 h was determined by measuring fluorescence in the
bottom chamber at 485/538 nm. *P,0.01.
doi:10.1371/journal.pone.0017921.g003
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able to cross the BBB. However, dye can extravasate into the brain
tissue if the BBB permeability is increased. Mice were injected with
purified InhA and EB dye was injected i.v. approximately 1 h
before euthanization. Digital images were taken immediately after
the brain was excised from the body to visualize the amount of dye
that penetrated into brain parenchyma (Figure 4A). The amount
of extravasated EB dye extracted from the brain tissues was
determined colorimetrically. Mice challenged with purified InhA
had a significant 2-fold increase in dye leakage compared to
control observed up to 72 h post challenge (Figure 4B).
Histological approaches were next used to examine correlation
of the observed InhA effect with anthrax CNS pathology. Mice
were injected with fluorescent nanoparticles conjugated with
purified InhA. Fluorescence microscopy was used to examine the
effect of InhA-conjugated nanoparticles on the BBB, as well as to
visualize InhA localization within the mouse brain. Histological
analysis of brain tissues showed that mice treated with either
unconjugated nanoparticles (Figure 5A) or heat-inactivated InhA-
conjugated nanoparticles (Figure 5B) did not exhibit any
pathological change thereby eliminating nonspecific effects of
nanoparticles or trauma of the brain due to injection. On the other
hand, mice injected with nanoparticle-conjugated to InhA showed
considerable leptomeningeal hemorrhaging, thickening, and
infiltration of inflammatory cells (Figures 5C, D). These mice also
displayed hemorrhages of the brain parenchyma (Figures 5E, F).
Immunofluorescence analysis of similar sections indicated accu-
mulation of active InhA-conjugated nanoparticles in areas
corresponding to meningeal thickening and hemorrhage in brain
microvasculatures (Figure 5I, J). No prominent nanoparticle
fluorescence was detected in the brains of mice treated with
nanoparticles alone or in mice treated with the heat-inactivated
InhA-conjugated nanoparticles (Figure 5G, H). These results show
that the nanoparticle-conjugated InhA is able to cross the BBB,
gain access to the CNS parenchyma and induce anthrax
meningitis-associated brain pathology due to activity of InhA [26].
InhA mutant bacteria display an attenuated response in
mice
To demonstrate contribution of InhA to anthrax meningitis in
vivo, mice were injected intravenously via the tail vein with early-
log-phase vegetative bacteria of wildtype and DinhA B. anthracis
Ames 35 strains. The intravenous route of infection and the choice
of vegetative cells, as opposed to the commonly used challenge
with spores, were chosen to model the late stage of the infectious
process when systemic bacterial dissemination to the brain may
lead to meningitis.
Mortality curves showed that the DinhA strain exhibited a
prolonged mean time-to-death compared to the wildtype suggest-
ing that InhA contributes to B. anthracis virulence (Figure 6A). The
effect of InhA deletion was most reliable (p=0.015) at the dose
providing 80% mortality after challenge with the parental strain,
when animals were not overwhelmed with a high dose of
pathogen. Blood and brains obtained from moribund animals at
48–72 h post infection were analyzed for bacterial load. Five out of
eight WT-infected mice had high bacterial counts in the brain,
while in the case of DinhA-infected mice only one animal
demonstrated presence of bacteria in the brain (Figure 6B). Upon
microscopic examination of brain tissues, five out of six WT-
infected mice (84%) showed meningeal thickening, compared to
only one out of five DinhA-infected mice (20%). In moribund mice,
WT infection (Figure 7A, D) showed more severe features of
meningeal thickening compared to DinhA infection (Figure 7E, F).
Collectively, these data demonstrate that InhA is involved in
breaching the BBB and hemorrhagic brain damage contributing
to the development of meningitis and B. anthracis virulence.
Figure 4. EB extravasation in the brains of InhA-challenged mice. Brain vascular permeability was measured using EB dye extravasation from
whole mouse brains after challenge with InhA through retro-orbital injection. (A) Representative pictures of mouse brains at indicated time points. (B)
Quantitation of the EB dye extravasation in the brain. The mean 6 SD are presented as mg of EB dye per gram of brain (n=5 in the InhA-injected
groups; n=3 in the control group). *P,0.05 vs. control group.
doi:10.1371/journal.pone.0017921.g004
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conjugated to (active and heat-inactivated) InhA (1 U in 100 ml) were injected via retro-orbital route (n=5). After 24 h, animals were euthanized and
brains were harvested, fixed, and 5-mm sections were stained with hematoxylin and eosin (H&E) (A–F) or immunostained for InhA (G–J). Representative
images are shown. (A) Brain of a mouse injected with unconjugated nanobeads. (B) Brain of a mouse injected with nanobeads conjugated to heat-
inactivated InhA (C, E) Brain of mouse injected with nanobeads conjugated to active InhA, showing hemorrhagic areas. (D, F) Enlargements of marked
areas in C and E, respectively. Meningeal thickening, hemorrhages and leukocyte infiltration are shown by double, red, and blue arrows, respectively.
(G–J) Immunofluorescent visualization of nanobeads (red) and InhA (green). (G) Brain meninges from a mouse injected with nanobeads alone. (H) Brain
meninges from a mouse injected with heat-inactivated InhA-conjugated beads. (I) Brain meninges from a mouse injected with active InhA-conjugated
nanobeads. (J) Brain parenchyma of a mouse injected with active InhA-conjugated nanobeads. Infiltration of InhA-conjugated nanobeads in meninges
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InhA is a secreted pathogenic factor of closely related Gram-
positive bacteria, B. thuringiensis, B. cereus and B. anthracis [24]. It
contributes to pathogenicity through several mechanisms, includ-
ing the cleavage of antibacterial proteins, escape of bacteria from
macrophages, control of blood coagulation, and degradation of
matrix-associated proteins [12,13,24,27–28]. However, a possible
role for InhA in development of anthrax meningitis has not been
demonstrated. We undertook this investigation to get insight into
potential molecular targets of InhA in the BBB during dissemi-
nated B. anthracis infection. We suggest a novel mechanism of BBB
breaching which involves InhA mediated proteolytic cleavage of
the TJ protein ZO-1. To date, no other CNS pathogen is known
to use this process to cross the BBB.
Our conclusion is supported by several lines of evidence. We
first demonstrated that purified InhA caused a marked drop in
TEER and morphological changes in cultured HBMECs which
were absent in the case of another major B. anthracis protease,
Npr599. These data indicate that InhA specifically targets the BBB
protein(s) responsible for permeability of HBMEC monolayers in
vitro. Previous studies have established that the barrier function of
BBB can be attributed to the TJ proteins of endothelial cells.
Alteration of TJ takes place in many CNS diseases, particularly in
meningitis [15]. Our analysis of major TJ proteins revealed a
unique susceptibility of ZO-1, but not occludin, claudin-1 or JAM-
1, to InhA proteolytic degradation. Experiments with HBMECs
pre-treated with cytochalasin D indicate that degradation of the
intracellular ZO-1 protein by exogenous InhA requires an
endocytic process that involves actin polymerization.
Our TEER measurements of HBMEC monolayers exposed to
growing bacteria are also consistent with the suggested role of
InhA in breaching the BBB. However, interpretation of these
results is complicated by the fact that B. anthracis produces a
number of pathogenic factors capable of compromising barrier
function of epithelial and endothelial cells. In addition to LT and
ET [29,30], these factors include proteolytic and hemolytic
enzymes as well as the pore-forming toxin, anthrolysin O [6,31].
These difficulties were mainly avoided using the recombinant,
non-pathogenic B. subtilis secreting InhA into culture medium. As
expected, this strain induced a substantial acceleration of TEER
drop in comparison with wildtype B. subtilis 168.
The next line of evidence includes the effect of purified InhA
administration on BBB integrity in vivo. Histopathological
examination of brain sections showed thickening of meninges
and hemorrhage after treatment with InhA. These results are
almost identical to the pathologies displayed in mice infected with
B. anthracis [26]. In comparison with InhA, mice and rats treated
with anthrax toxins develop widespread tissue disruption and
vascular damage with focal hemorrhaging; however, histopatho-
logical lesions in brain meninges have not been reported [29,30].
Finally, we used the murine model of disseminated anthrax
where vegetative bacteria were injected intravenously to mimic the
late stage of the disease. Previous studies of the B. anthracis
secretome show that InhA is one of the abundant proteins
expressed in vivo during B. anthracis infection [32]. Using inhA
mutants of B. anthracis in comparison with wildtype we demon-
strated that inhA deletion is associated with decreased virulence as
well as lower bacterial loads in the blood and brain. Microscopic
and parenchyma is visible as numerous dots and areas of yellow color (overlapping red and green) indicated by arrows. Scale bar, 100 mm. DAPI was
used to visualize cell nuclei.
doi:10.1371/journal.pone.0017921.g005
Figure 6. InhA contributes to virulence of B. anthracis infection in mice. Animals were injected intravenously into the tail vein with indicated
CFU of the early-log-phase vegetative bacteria of Ames 35 (WT) and DinhA strains, correspondingly. Mice were monitored twice daily for mortality
and survival. (A) Kaplan–Meier survival curve (n=5 in both groups). Control mice (n=3) injected intravenously with PBS did not die (data not shown).
Data were analyzed using the log-rank test. (B) Bacterial load in brains (left panel, n=8) and blood (n=5, right panel) in mice challenged with
5610
5 CFU as in (A) at 48 h post challenge. Bar in (B) represents median bacterial CFU.
doi:10.1371/journal.pone.0017921.g006
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the development of meningitis. However, the effect of inhA deletion
may not be limited just to the BBB permeability. Lower bacterial
loads indicate that the overall less virulent mutant bacteria do not
survive as well in the blood and therefore may not even reach the
brain. On the other hand, InhA was previously implicated in the
survival of germinating spores within host macrophages at the
early stage of infection [24]. Therefore, in the comparative
experiments with the DinhA mutant and wildtype strains aimed to
reveal the late effect of InhA in the brain, it was important to avoid
the contribution of the macrophage-related effect of InhA, which
could potentially lead to misinterpretation of results due to
increased killing of the DinhA mutant by macrophages.
Although the detailed mechanism of anthrax meningitis remains
to be elucidated, available data allow us to suggest that the effect of
InhA on the brain may have relevance to its capacity to induce
thrombosis and blood coagulation [11–13,28]. One of the key
features found in clinical autopsies of patients dying of anthrax
meningitis are massive hemorrhages, clotting, and swelling of the
leptomeninges and intra-parenchymal regions of the brain
associated with disseminated intravascular coagulation [33–35].
It can be surmised that once bacteria reach areas of the capillaries
where they can no longer physically move, local secretion of InhA
can quickly exceed the threshold level causing blood coagulation
and local vascular damage [13], thus allowing the bacteria to
spread to brain parenchyma. However, it seems certain that
breaching of the protective barriers in the infected host represents
a complex picture resulting from a combined activity of multiple
pathogenic factors at different stages of disease. In addition to the
InhA-mediated proteolytic damage, the results of ours and others
indicate that mechanisms contributing to the BBB permeability in
anthrax may include the host acute-phase response induced by
InhA [28], the effects of LT on endothelial cells [36,37], loss of
extracellular syndecan [11,35,38], perturbation of cell-cell
signaling in adherence junctions [39], and oxidative cell damage
by anthrolysin O and bacterial fermentation products [31].
Biologically relevant concentrations of these factors at the sites of
pathology and their relative contribution to mortality as well as
their interplay with the major effects of LT and ET, need to be
addressed in future studies.
In conclusion, we report here that InhA-induced BBB
disruption provides a mechanistic model relevant to anthrax
meningitis. We have identified a protease, its primary substrate,
and its unique barrier permeability property in the closely
structured human brain endothelia. The results of our in vitro
experiments with HBMECs, as well as in vivo findings in mice
lead us to conclude that InhA invades the endothelial cells,
degrades the TJ protein ZO-1, and thus contributes to
hemorrhage in the CNS. Taken together, the reported results
add a new dimension to our understanding of hemorrhagic
meningitis in B. anthracis infections. As InhA appears to be a
potential pathogenic factor, it can be a molecular target for
prevention of, and therapy against fatal hemorrhages associated
with B. anthracis infection.
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Figure 7. InhA contributes to BBB breakdown during B. anthracis infection in mice. Histopathology of representative H&E-stained brain
sections from mice challenge as in Figure 6. (A, B) Control mice; (C, D) Moribund mice challenged with B. anthracis Ames 35. Meningeal thickening is
shown by double arrows. (E, F) Moribund mice infected with B. anthracis DinhA. Boxes in C, E show the areas enlarged in D, F, respectively.
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